US phase II trial starts for MRA contrast agent:
This article was originally published in Clinica
Executive Summary
Advanced Magnetics has begun a phase II clinical trial in the US to test its investigational contrast agent in MR angiography (MRA). The agent, currently known as Code 7228 is a coated iron oxide product. The Cambridge, Massachusetts-based company says that preliminary results concerning the agent's safety profile and blood pool persistence - two critical elements in evaluating cardiovascular imaging agents - suggest that the product shows promise for use in cardiovascular imaging applications such as MRA.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.